期刊文献+

1型肝肾综合征患者内毒素和内皮素1水平分析 被引量:4

Analysis of endotoxin and endothelin-1 levels in patients with type 1 hepatorenal syndrome
下载PDF
导出
摘要 目的分析肝硬化腹水伴1型肝肾综合征(HRS)患者的临床资料、实验室指标、感染发生率、血清降钙素原(PCT)和内皮素1(ET-1)水平,探讨内毒素和ET-1在HRS发生中的作用。方法纳入本院2009年1月至2012年10月住院的肝硬化腹水伴1型HRS患者56例(HRS组)及肝硬化伴腹水且肾功能正常患者60例(非HRS组),收集2组患者的一般资料、肝硬化病因、感染发生率及类型、Child-Pugh分级、全身炎症反应综合征(SIRS)评分及平均动脉压(MAP);同时采集2组患者血液,分析肝肾功能、电解质、PCT、ET-1水平。比较2组患者的临床资料和检测指标。计数资料采用χ2检验,正态分布计量资料组间比较采用成组t检验,非正态分布计量资料组间比较采用Wilcoxon秩和检验。结果 HRS组感染发生率为75.0%,显著高于非HRS组的28.4%(χ2=11.91,P<0.05)。HRS组PCT、ET-1和SIRS分别为8.72(3.14,31.68)ng/L、(13.04±2.82)pg/ml和2.1±1.1,高于非HRS组的0.11(0.04,0.45)ng/L、(5.76±1.68)pg/ml和0.6±0.6(P<0.05)。实验室指标中,HRS组血清尿素、肌酐、半胱氨酸蛋白酶抑制剂及钾水平高于非HRS组,差异有统计学意义(P<0.05);而HRS组的Na、Cl水平低于非HRS组,差异有统计学意义(P<0.05),两组间ALT、AST差异无统计学意义(P>0.05)。结论内毒素诱导ET-1表达增加,ET-1强烈收缩肾血管引发肾灌注不足,导致1型HRS的产生。内毒素和ET-1与1型HRS发生关系密切。 Objective To analyze the clinical data, laboratory parameters, infection rate, and serum procalcitonin (PCT) and ET - 1 levels of patients with cirrhotic ascites and type 1 hepatorenal syndrome (HRS) and to investigate the roles of endotoxin and ET- 1 in the develop- ment of HRS. Methods Between January 2009 and October 2012, 56 inpatients with cirrhotic ascites and type 1 HRS ( HRS group) and 60 inpatients with cirrhotic ascites who had normal renal function (non- HRS group) were included in the study. Their general data, causes of liver cirrhosis, infection rates and types, Child -Pugh classification, systemic inflammatory response syndrome (SIRS) score, and mean arteri- al pressure (MAP) were recorded; blood samples were collected to evaluate liver and renal function and measure serum electrolyte, PCT, and ET- 1 levels. The clinical data and laboratory parameters were compared between the two groups. Categorical data were analyzed by chi - square test ; comparison of normally distributed continuous data between the two groups was made by independent - samples t test, and compari- son of non - normally distributed continuous data between the two groups was made by Wilcoxon rank sum test. Results The infection rate of HRS group (75.0%) was significantly higher than that of non -HRS group (28.4%) (X2 = 11.91, P 〈 0.05 ). The PCT and ET - l levels and SIRS score of HRS group [8.72 (3.14, 31.68) ng/L, 13.04 ±2.82 pg,/ml, and 2.1 _+ 1.1 ] were significantly higher than those of non - HRS group [ 0.11 (0.04, 0.45 ) ng/L, 5.76±1.68 pg/mi, and 0.6 ~ 0.6 ] ( P 〈 0.05 ). In addition, the HRS group had significantly higher serum urea, creatine, cystatin C, and K levels than the non - HRS group (P 〈 0.05 ) , while the HRS group had significantly lower Na and C1 levels than the non - HRS group ( P 〈 0.05 ). There were no significant differences in ALT and AST levels between the two groups ( P 〉 0. 05 ). Conclusion Endotoxin causes elevated expression of ET - 1, and ET - 1 induces renal perfusion deficiency by intense renal vasocon-striction, thus leading to type 1 HRS. Endotoxin and ET - 1 are closely associated with the development of type 1 HRS.
出处 《临床肝胆病杂志》 CAS 2014年第1期58-61,共4页 Journal of Clinical Hepatology
基金 四川省科技支撑项目(2010SZ0252)
关键词 肝肾综合征 肝硬化 内毒素类 肉皮缩血管肽1 hepatorenal syndrome liver cirrhosis endotoxins endothelin - 1
  • 相关文献

参考文献5

二级参考文献57

共引文献92

同被引文献47

  • 1骆健峰,龚永生.尾加压素Ⅱ研究新进展[J].国外医学(内科学分册),2005,32(1):10-13. 被引量:4
  • 2孙波,慎睿哲,吴云林.血管活性药物治疗肝肾综合征[J].胃肠病学,2005,10(2):127-128. 被引量:5
  • 3章友康.肝肾综合征的诊断、分型和治疗进展[J].中国实用内科杂志,2006,26(3):337-340. 被引量:16
  • 4刘成海,姚树坤.肝硬化腹水的中西医结合诊疗共识意见.中国中西医结合杂志,2011,23(09):1190-1192.
  • 5Salerno F, Gerbes A, nosis, prevention and syndrome in cirrhosis (9): 1310 -1318. Ginbs P, et al. Diag- treatment of hepatorenal [ J]. Gut, 2007, 56.
  • 6GINES P, GUEVARA M, ARROYO V, et al. Hepatorenal syndrome[J]. Lancet, 2003, 362(9398). 1819 -1827.
  • 7GINES P, GUEVARA M. Good news for hepatorenal syn- drome[J]. Hepatology, 2002, 36(2). 504-506.
  • 8SARIN SK, SHARMA P. Terlipressin. an asset for hepatolo- gists! [J]. Hepatology, 2011, 54(2);724-728.
  • 9SANYAL A J, BOYER T, GARCIA -TSAO G, et al. A ran- domized, prospective, double - blind, placebo - controlled trial of terlipressin for type 1 hepatorenal syndrome[J]. Gas- troenterology, 2008, 134(5}. 1360-1368.
  • 10ALESSANDRIA C, OTIOBRELLI A, DEBERNARDI-VENON W, et al. Noradrenalin vs terlipressin in patients with hepato- renal syndrome., a prospective, randomized, unblinded, pilot study[J]. J Hepatol, 2007, 47(4) : 499 -505.

引证文献4

二级引证文献36

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部